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Protein tyrosine phosphatases (PTPs) are important regulators of cell functions but data on different PTP expression and dynamics in acute
pancreatitis (AP) are very scarce. Additionally, both c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinases (ERK1/2), together
with intracellular cAMP levels in inflammatory cells, play an essential role in AP. In this study we have detected an increase in PTP SHP-1 and
SHP-2 in the pancreas at the level of both protein and mRNA as an early event during the development of Cerulein (Cer)-induced AP in rats.
Nevertheless, while SHP-2 protein returned to baseline levels in the intermediate or later phases of AP, SHP-1 protein expression remained
increased throughout the development of the disease. The increase in SHP-2 protein expression was associated with changes in its subcellular
distribution, with higher percentages located in the fractions enriched in lysosomes+mitochondria or microsomes. Furthermore, while the increase
in SHP-2 protein was also observed in sodium-taurocholate duct infusion or bile-pancreatic duct obstruction AP, that of SHP-1 was specific to the
Cer-induced model. Neutrophil infiltration did not affect the increase in SHP-1 protein, but favoured the return of SHP-2 protein to control levels,
as indicated when rats were rendered neutropenic by the administration of vinblastine sulfate. Inhibition of JNK and ERK1/2 with SP600125 pre-
treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV
phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase. Our results show that AP is
associated with increases in the expression of SHP-1 and SHP-2 and changes in the dynamics of SHP-2 subcellular distribution in the early phase
of Cer-induced AP. Finally, both JNK and ERK1/2 and intracellular cAMP levels are able to modulate the expression of these PTPs.
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In the pathogenesis of acute pancreatitis (AP) many factors,
including activated pancreatic enzymes, cytokines, chemokines,
free radicals, blood flow, and neurogenic factors, have been
reported. Nevertheless, the pathophysiology of the disease
remains incompletely understood, especially the early acinar
events. It has been suggested that it would be important to detect⁎ Corresponding author. Departamento de Bioquímica y Biología Molecular,
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doi:10.1016/j.bbadis.2008.01.005rapid early events and signalling mechanisms in AP because
these events would probably be translated into long-term res-
ponses that would determine the development of pancreatitis
[1].
One of the animal models of AP is that induced by supra-
maximal secretagogue stimulation. Usually, the trophic agent
cerulein [Cer, an analogue of cholecystokinin (CCK)] is used
in this model. Different doses of Cer (ranging from 5 to even
100 μg/Kg) have been used to induce AP in rats. Under the
conditions used here [20 μg/Kg subcutaneous (s.c.) injection] the
manifestations of pancreatitis include hyperamylasemia, inter-
stitial edema, increase pancreatic cell size, increased pancreatic
weight, histological damages, including increased vacuolization
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tration [2–5]. With current ongoing research, the intracellular
mechanisms by which CCK or Cer regulate pancreatic acinar
function appear to be increasingly complex. ThroughGq proteins,
CCK and Cer lead to an increase in cytosolic free Ca2+. Ca2+,
diacylglycerol and cAMP activate exocytosis processes. More-
over, it is known that both CCK and Cer activate pancreatic
protein tyrosine kinases (PTK) [6,7] and that tyrosine phospho-
rylation plays important roles in the regulation of many cell
functions. Cer-induced AP also activates the mitogen-activated
protein kinase (MAPKs) cascade, especially extracellular signal-
regulated kinase (ERK1/2) and c-Jun N-terminal kinase (JNK),
whose activation requires the phosphorylation of both tyrosine
and threonine residues [8,9]. p38MAPK is also activated by
CCK and Cer. Other signalling pathways are also activated in
AP, e.g. the adenosineA1-receptor pathway [10], which decreases
intracellular cAMP levels. In this regard, it is known that type IV
phosphodiesterase inhibitors ameliorate Cer-induced AP [11].
It is also clear that pancreatitis requires the dissociation of cell–
cell contacts [12] and adherens junctions [13], and that tyrosine
phosphorylation is important for the maintenance of an intact
cell adhesion complex [14].
The discovery of the role of PTK in the regulation of the
levels of tyrosine phosphorylation has led phosphotyrosine
phosphatases (PTP) to become better appreciated as impor-
tant regulators of cell functions. The structurally very similar
SH2-domain containing PTPs SHP-1 and SHP-2 have been
proposed to have different roles in signal transduction: SHP-1
is expressed highly in hematopoietic cells and at a moderate
level in many other types of cells and plays a largely negative
signalling role in hematopoietic cells. SHP-2 is more widely
expressed and plays a largely positive role in the cell signall-
ing leading to cell activation. Nevertheless, it seems that the
functional nature of SHP-1 and SHP-2 depends on the systems
involved. SHP-1 has been implicated in the Jak-Stat and MAPK
pathways [15]. SHP-2 has compound signalling functions and
it appears to be involved in a variety of signal transduction
processes, such as the Ras-Raf-MAPK, Jak-Stat, PI3 kinase and
NF-κB pathways [16]. Even within a single signalling pathway,
SHP-2 may act at multiple sites to participate in signal trans-
duction. All the above SHP-1 and SHP-2 signalling pathways
have been implicated in the development of AP.
Data on PTP in AP are very scarce although it is well
documented that these signalling enzymes are inactivated by
reactive oxygen species (ROS) [17] or secondary products of
oxidation [18,19] that may form during AP development [20,21].
Essentially, only one function of SHP-1 and PTPκ in the re-
gulation of cell adhesion in the pancreas after mild experimental
Cer-induced pancreatitis in rats has been described [12]. No data
are available about changes in the expression of SH2-domain
PTPs either at the level of RNA or protein, and neither is the
dynamics of their subcellular location along the development of
pancreatitis known. Considering the importance of determining
molecules or genes whose expression changes in the early phase
of AP development, together with the signalling mechanisms
that may modulate such expression, here we studied the ex-
pression and dynamics of the subcellular location of SHP-1 andSHP-2 in the development of Cer-inducedAP, aswell as the effect
of SP600125 (anthrax[1,9cd]pyrazol-6(2H)-one 1,9 pyrazoloan-
throne), a new JNK and ERK 1/2 inhibitor, and rolipram, a type
IV phosphodiesterase inhibitor, on SHP-1 and SHP-2 expression
levels in the early phase of AP development.
2. Materials and methods
2.1. Reagents
Bovine serum albumin (BSA), Cer, dithiothreitol (DTT), Percoll, phenyl-
methylsulfonyl fluoride (PMSF), Protein Inhibitor Cocktail, rolipram, sodium-
taurocholate, soybean trypsin inhibitor, SP600125, Trizol Reagent, vinblastine
sulfate were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Polyvinylidene difluoride (PVDF) membranes were obtained from Amersham
Biosciences, Spain. Monoclonal antibody anti-PTP-1 (D-11) was obtained from
Santa Cruz Biotechnology, Inc, CA, USA. Monoclonal antibody anti-PTP-2
was obtained from BD Biosciences Pharmingen, San Diego, CA, USA. Re-
verse Transcriptase (RevertAid M-MULV), Taq polymerase, dNTP's and the
Ribolock Ribonuclease inhibitor used in the reverse transcriptase-polymerase
chain reaction (RT-PCR) were purchased from Fermentas Life Sciences,
Germany. Oligonucleotides were obtained from Isogen life Sciences, The
Netherlands. Isopropanol was purchased from Panreac, Spain. The Myeloper-
oxidase (MPO) Fluorimetric Detection Kit was purchased from Assay Desigs,
Inc, USA.
2.2. Animals
Male Wistar rats weighing 250–280 g were used. The animals were given a
standard rat chow diet and were fasted overnight before experiments with free
access to water. Care was provided in accordance with the procedures outlined
in European Community guidelines on ethical animal research (86/609/EEC),
and protocols were approved by the Animal Care Committee of the University
of Salamanca.
2.3. Induction of AP and preparation of samples
Rats received 4 s.c. injections of 20 μg Cer/kg bodyweight or its vehicle (0.9%
NaCl) at hourly intervals. At 2, 4 or 9 h after the first injection, the animals
were killed by cervical dislocation. The pancreases were rapidly harvested and
immediately used for experiments. Serum samples were stored at −80°C until
amylase determination. In some cases, AP was also induced by sodium-tau-
rocholate duct infusion or bile-pancreatic duct obstruction (BPDO) [22,23, res-
pectively]. Pancreases were dissected out from the surrounding fat tissue and
then homogeneized with a Potter Elvehjem device in 10 volumes (v/w) of
homogenization buffer (3mM imidazole buffer, pH 7.4 containing 0.25M sucrose,
1 mM EDTA, 1 mM PMSF, 100 μg/ml trypsin inhibitor and 2 μl/ml Protease
Inhibitor Cocktail). The subcellular fractionation was done in a postnuclear
homogenate from 4 pancreases as described before [21]. Four subcellular fractions
were obtained: the zymogen (Z), lysosomes plusmitochondria (L+M),microsomes
(Mic) and soluble (S) fractions.
Serum amylase was measured in the Roche Modular Analyzer by the method
of Lorentz [24]. In brief, the oligosaccharide 4,6-ethylidene-(G7) p-nitrophenyl-
(G1)-α, D-maltoheptaoside (ethylidene-G7PNP) was cleaved under the catalytic
action of α-amylases. The G2PNP, G3PNP γG4PNP fragments so formed were
then completely hydrolysed to p-nitrophenol and glucose by α-glucosidase. The
color intensity of the p-nitrophenol formed is directly proportional to theα-amylase
activity andwasmeasured photometrically. Protein concentrationswere assayed by
the method of Bradford [25], using BSA as standard.
2.4. Induction of neutropenia
Vinblastine sulfate was dissolved in 10 mM sodium phosphate buffer,
147mMNaCl, 2.7 mMKCl (pH 7.4) and administered to rats intravenously (i.v.)
at a dose of 0.75 mg/kg on day 1, as previously described [26]. At this dose,
animals become neutropenic between days 4 and 6 [26]. On day 5 following
Fig. 1. Expression of SHP-1 (A) and SHP-2 (B) proteins and serum amylase
activity (C) during the development of Cer-induced AP. Rats were either
administered saline (0.9% NaCl) (control, C) or treated with Cer, as indicated in
Materials and methods, and then killed 2, 4 or 9 h after the first injection of Cer.
In (A) and (B), quantification (graphic) of expression (Western blots in whole
postnuclear pancreatic homogenates— a representative for each time is shown)
was carried out considering the whole pancreas. Each lane in the blots contained
30 μg of proteins. Data are means±S.D. of 5 animals.
Fig. 2. SHP-1 (A) and SHP-2 (B) mRNA expression in the early phase of Cer-
induced AP. Rats were either administered saline (0.9% NaCl) (control, C) or
treated with Cer (P), as indicated in Materials and methods, and then killed 2 h
after the first injection of Cer. mRNA expression was analysed in pancreas or
brain by RT-PCR. A representative RT-PCR is shown.
273N. Sarmiento et al. / Biochimica et Biophysica Acta 1782 (2008) 271–279vinblastine sulfate or saline administration, the animals were treated with 2 doses
of Cer (20 μg Cer/kg, administered at hourly intervals) to induce AP.
2.5. Inhibition of JNK- and ERK1/2 by SP600125 in Cer-induced AP
Rats received intraperitoneal (i.p.) injections of SP600125 (15 mg/kg) or its
vehicle (1 ml/kg of a 10% DMSO/NaCl solution) both 2 h before and 30 min
after the first Cer injection [9]. Two hours after the first injection of SP600125,
the rats were injected subcutaneously with Cer (20 μg Cer/kg) or its vehicle
(0.9% NaCl) at hourly intervals. The animals were sacrificed 2 h after the first
Cer injection (early phase of Cer-induced AP).
2.6. Inhibition of type IV phosphodiesterase by rolipram in Cer-induced
AP
Rats received i.p. injections of rolipram (5 mg/kg) or its vehicle (1 ml/kg of a
10% DMSO/NaCl solution) both 30 min before and 30 min after the first Cer
injection [27]. Thirty minutes after the first injection of rolipram, the rats wereinjected subcutaneously with Cer (20 μg Cer/kg) or its vehicle (0.9% NaCl) at
hourly intervals. The animals were sacrificed 2 h after the first Cer injection
(early phase of Cer-induced AP).
2.7. RNA preparation and RT-PCR
Total RNAwas isolated from the pancreas and brain of the same rat by immediate
solubilization in Trizol Reagent and isopropanol purification. RNA concentrations
were determined by absorbance, and RNA integrity was checked by agarose
electrophoresis. Reverse transcriptionwas completed by incubating 2μgof totalRNA
with 0.5 μg of a 18-mer oligo(dT) primer at 42 °C for 1 h, using 200 U of RevertAid
M-MuLV Reverse Transcriptase in a solution containing 50 mM Tris–HCl, pH 8.3,
50 mM KCl, 4 mM MgCl2, 10 mM DTT, 1 mM individual dNTPs and 20 U of
Ribolock Ribonuclease inhibitor in a final volume of 20μl. The reaction was stopped
by heating at 70 °C for 10 min. Four microliters of this reaction was then used as a
template for the polymerase chain reaction, which was performed with 1 U of Taq
polymerase in a final volume of 40 μl with specific oligos at a 0.4 μM final
concentration. The annealing temperature was 54 °C. Five microliters samples were
taken at 25, 29, 32 and 35 cycles to ensure that we were working within the semi-
quantitative range. The oligonucleotide sequences were as follows: SHP-1: forward
oligo: AGGCCGGCTTCTGGGAGGAGTT; reverse oligo: CCAGTGGGGA-
GATCTGCAATGTTC. SHP-2: forward oligo: TGACCTCTATGGCGGG-
GAAAAGTT; reverse oligo: TCAGCGGCATTAATACGAGTTGTG. Product
lengths were 400 and 486 pb for SHP-1 and SHP-2, respectively.
2.8. Myeloperoxidase (MPO) assay
Excised pancreatic tissue samples were rinsed with saline, blotted dry, snap-
frozen in liquid nitrogen, and stored at−80 °C.MPOactivitywas detected by using
the MPO Fluorimetric Detection Kit following the manufacturer's instructions.
2.9. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
SHP-1 and SHP-2 were analysed by SDS-PAGE using 10% gels [28]. The
proteins present in the gels were transferred to PVDF membranes. After block-
ing non-specific binding with 5% non-fat dry milk (dissolved in buffer 10 mM
Tris–HCl, 100 mM NaCl, 0.1% Tween 20, pH 7.5), Western blots were probed
with anti-SHP-1 or anti-SHP-2 monoclonal antibodies diluted 1:150 and 1:2500,
respectively, in the blocking solution. Blots were visualized by chemilumines-
cence. To analyse the spots on all the blots, film images were scanned using the
Fig. 3. Expression of SHP-1 (A) and SHP-2 (B) proteins in different models of AP.
Three different AP models were used: Cer-induced (Cer), sodium-taurocholate
duct infusion (Tau) or bile-pancreatic duct obstruction (BPDO) pancreatitis. Saline
(0.9%NaCl)- injected rats are also shown (control, C). Cer represents 9 h treatment
with Cer, as indicated in Materials and methods. Quantification (graphic) of
expression (Western blots in whole postnuclear pancreatic homogenates — a
representative is shown) was carried out considering thewhole pancreas. Each lane
in the blots contained 30 μg of proteins. Data are means±S.D. of 3 animals.
Fig. 4. Effect of neutropenia on MPO (A) and serum amylase (B) activities, and SHP
AP. Rats were given 0.75 mg/kg i.v. vinblastine sulfate to induce neutropenia. Four da
of saline (0.9% NaCl) or Cer hourly over 4 h (representing the intermediate phase of
control animals (C) (saline instead of vinblastine pre-treatment on day 1). In (C) and
pancreatic homogenates— a representative is shown) was carried out considering t
means±S.D. of 3 animals. N.S., not significant.
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with the MacBas v 2.5. program, as described previously [29]. The images
shown in the figures are from blots whose films were exposed for optimal
reproduction rather than for the linearity of band densities.
2.10. Statistical analysis
Data are expressed as means±SD. They were analysed using the non-
parametric Mann–Whitney U test. Statistical significance was considered for
a p value b0.05. Analyses were implemented using the SPSS program for
MS Windows (version 15.0).3. Results
3.1. SHP-1 and SHP-2 expression during the development of
AP
The upper parts of Fig. 1A and B show representative
Western blot analyses indicating both SHP-1 and SHP-2 pro-
teins in whole postnuclear pancreatic homogenates obtained
from control or pancreatitic rats at different times after the first
injection of Cer. The lower parts of Fig. 1A and B indicate
quantitative data related to the whole pancreas. We considered
it more appropriate to express the data in relation to the
whole pancreas because pancreatitis is associated with the
neutrophil infiltration and cell death that make the cell com-
position of the pancreases of control or pancreatitic rats dif-
ferent. We observed an increase in the expression of both SHP-1
and SHP-2 in the early phase of AP (2 h after the first injection
of Cer) (6.1±2.4- and 3.3±1.6-fold that of controls for SHP-1
and SHP-2, respectively). For SHP-1, this early increase in
expression remained in the intermediate and later phases of-1 (C) and SHP-2 (D) protein expression during the development of Cer-induced
ys after vinblastine administration, these neutropenic rats were given 4 injections
AP) as indicated in Materials and methods. The same treatments were given to
(D), quantification (graphic) of expression (Western blots in whole postnuclear
he whole pancreas. Each lane in the blots contained 30 μg of proteins. Data are
Fig. 5. Effect of SP600125 pre-treatment on SHP-1 (A) and SHP-2 (B) protein
expression in the early phase of Cer-induced AP. Rats were pretreated with
SP600125 or its vehicle (15 mg/kg or 1 ml/kg of 10% DMSO/NaCl solution i.p.
administered 2 h before and 30 min after the first injection of Cer, respectively).
Then, the animals were injected subcutaneously with either Cer or its vehicle
[20 mg/kg or saline (0.9% NaCl, Sal) for each of two injections at hourly
intervals, respectively]. As a positive control of the experiment, non-pretreated
rats (Sal and Cer) were also included. Quantification (graphics) of expression
(Western blots in whole postnuclear pancreatic homogenates— a representative
is shown) was carried out considering the whole pancreas. Each lane in the blots
contained 30 μg of proteins. Data are means±S.D. of 2 experiments with 3 rats
per group in each.
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control at 9 h). By contrast, SHP-2 expression fell to levels
similar to those of the controls from 4 h onwards. Fig. 2A and B
depict representative gels highlighting mRNA expression for
both SHP-1 and SHP-2 in the early phase of AP (2 h). It may be
observed that the induction of AP by Cer resulted in an increase
in SHP-1 and SHP-2 mRNAs in pancreas but not in a control
organ with Cer receptors (brain), in which the expression of
SHP-1 and SHP-2 proteins remained constant (data not shown).
Cer-induced AP is thus associated with increases in pancreatic
SHP-1 and SHP-2 at the level of both protein and mRNA.
Additionally, as proof of the establishment of AP, a significant
increase in serum amylase activity was observed along the
development of AP, Fig. 1C).
To analyse whether the increase in SHP-1 and SHP-2 pro-
tein expression was specific to the Cer AP model, we next
assayed the taurocholate and BPDO models of AP. For this,
the pancreases were studied once AP was fully developed.
As depicted in Fig. 3B, an increase in the expression of SHP-2
was also observed in the other two models of AP, mainly in
the BPDO model (4.5±1.4- and 11.9±5.6-fold that of con-
trols for the taurocholate and BPDO models, respectively). By
contrast, an increase in SHP-1 protein expression was not
detected either in the taurocholate or in the BPDO model of
AP; instead, a decrease was observed, especially in the BPDO
model. (Fig. 3A).
3.2. Influence of neutrophil infiltration
Neutrophil infiltration is an important component in the
development of both inflammation and cell death in pancreati-
tis. Thus, in an attempt to see whether infiltrating neutrophils
were responsible for, or could somehow influence, the increase
in the protein expression of both PTPs in Cer-induced AP,
rats were rendered neutropenic with vinblastine sulfate before
treatment. The rats were administered vinblastine on day 1, and
the experiment with Cer was conducted on day 5, at which point
it has been reported that animals have no remaining neutro-
phils [26]. As expected, a differential count of leukocytes in
the blood of the rats used in our experiments afforded zero
percent of neutrophils (39±5 and 0% neutrophils in blood from
Cer-induced AP (4 h) rats non-pretreated or pretreated with
vinblastine sulfate, respectively, n=3: data not shown).
Furthermore, leukocyte accumulation in the pancreas was
investigated by measuring MPO activity. We chose to study
the intermediate phase of AP (4 h) because it has been reported
that at this time the inflammatory cell infiltration has already
taken place [30]. In Fig. 4A it may be seen that while Cer
treatment (4 h) caused leukocyte accumulation in the pancreas,
the administration of vinblastine resulted in blunted pancreatic
MPO levels. With respect to serum amylase, vinblastine
treatment alone did not affect its activity, and Cer treatment in
vinblastine-treated rats did not decrease serum amylase
levels (Fig. 4B), in agreement with previously reported data
[26]. Fig. 4C shows that the depletion of neutrophils in the
rats did not significantly affect the increase in SHP-1 protein
expression at 4 h after Cer treatment (5.7±1.8- and 3.6±1.6-foldabove the controls in pancreatitic rats non-pretreated or
pretreated with vinblastine sulfate, respectively). In the case of
SHP-2 (Fig. 4D), neutrophil depletion prevented the decrease in
PTP expression down to basal levels at 2 h after Cer treatment,
because in the intermediate phase of AP (4 h) SHP-2 protein
expression was still significantly increased (1.1±0.1- and 4.1±
1.7-fold that of controls in pancreatitic rats non-pretreated or
pretreated with vinblastine sulfate, respectively).
3.3. Effect of JNK and ERK1/2 kinase inhibition by SP600125
It has been proposed that MAP kinases play a pivotal role
in the development of hyperstimulation-induced pancreatitis,
in part due to an amelioration of the severity of Cer-induced
AP after the inhibition of JNK and ERK1/2 kinases [9]. To
check whether these two MAP kinases might play a role in
the increase of the expression of both PTPs in the early phase
(2 h) of AP, we next investigated the effect of SP600125, a new
inhibitor of JNK and ERK1/2, on SHP-1 and SHP-2 protein
expression. In Fig. 5, it can be observed that SP600125 pre-
treatment did not reduce the increase in the expression of either
Fig. 6. Effect of rolipram pre-treatment on SHP-1 (A) and SHP-2 (B) protein
expression in the early phase of Cer-induced AP. Rats were pretreated with
rolipram or its vehicle (5 mg/kg or 1 ml/kg of 10% DMSO/NaCl solution i.p.
administered 30 min before and 30 min after the first injection of Cer,
respectively). Then, the animals were injected subcutaneously with either Cer or
its vehicle [20 mg/kg or saline (0.9% NaCl, Sal) for each of two injections at
hourly intervals, respectively]. As a positive control of the experiment, non-
pretreated rats (Sal and Cer) were also included. Quantification (graphics) of
expression (Western blots in whole postnuclear pancreatic homogenates -a
representative is shown) was carried out considering the whole pancreas. Each
lane in the blots contained 30 μg of proteins. Data are means±S.D. of 2
experiments with 3 rats per group in each.
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SHP-1 (Fig. 5A) and SHP-2 (Fig. 5B) was significantly in-
creased in the pancreases of Cer-injected rats pretreated with
SP600125 in comparison with the non-pretreated animals (6.2±
1.6- and 3.1±0.7-fold, and 7.1±2.5- and 2.1±1.1-fold as com-Table 1
Percentage distribution of SHP-2 protein in subcellular fractions from pancreas in c
Time after first injection of saline or Cae (h)
Subcellular
fraction
(%)
2 4
C P C
L + M 1.8±0.8 8.1±5.8a 0.7±
Mic 3.3±1.0 21.8±8.2b 1.9±
Z 1.0±0.7 2.6±2.5 0.4±
S 93.9±1.4 67.5±5.4a 97.1±
Subcellular fractions: L+M, lysosomes+mitochondria; Mic, microsomes; Z, zymogen
(Cer-injected).
Values were obtained from quantification of Western blots as indicated in Materials a
integrated densities for all subcellular fractions in the whole pancreases as 100%. D
apb0.021, bpb0.020 with respect to C at 2 h.pared with control rats for SHP-1 and SHP-2, respectively).
Moreover, JNK and ERK1/2 inhibition in the absence of
Cer stimulation was also able to increase SHP2 protein ex-
pression to a similar extent to Cer (2.6±0.8- and 2.1±1.1-, 2.3±
0.7-fold that of control rats injected with saline or saline+
vehicle (DMSO), for Cer and Cer+vehicle (DMSO) or saline+
SP600125 injected rats, respectively). This latter effect was
not observed for SHP-1. Regarding serum amylase activity in
the early phase (2 h) of AP, SP600125 was not able to reduce
the significant increase observed in the animals given Cer
alone (1603±10, 1710±56, 4800±300, 5500±400 U/l, n=3,
for rats given saline+DMSO, saline+SP600125, Cer+DMSO
and Cer+SP600125, respectively, data not shown).
3.4. Effect of type IV phosphodiesterase inhibition by rolipram
We next decided to analyse the role of cAMP levels in the
increase in the expression of both PTPs in the early phase (2 h)
of AP, since it has recently been proposed that intracellular
cAMP levels in inflammatory cells might also play an essen-
tial role in the pathogenesis of AP [27]. In Fig. 6A it can be
observed that rolipram, an inhibitor of type IV phosphodiester-
ase, did not affect the increase in SHP-1 protein expression
due to Cer, since in comparison with the non-pretreated animals
PTP protein expression was not modified in the pancreases
obtained from Cer-injected rats pretreated with rolipram (4.9±
1.5- vs 6.6±3.5-fold above control rats, respectively). Unlike
SHP-1, the increase in SHP-2 protein expression due to Cer was
significantly suppressed in rolipram-pretreated rats (Fig. 6B)
(1.3±0.3- vs 5.0±0.3-fold above control rats (injected with
saline+vehicle) for Cer+rolipram and Cer+vehicle rats, respec-
tively). Rolipram did not change SHP-2 protein expression in
the absence of Cer stimulation [1.2±0.1-fold in saline+
rolipram-injected rats as compared with saline+vehicle-injected
rats]. Regarding serum amylase activity in the early phase (2 h)
of AP, rolipram showed a tendency (although not significant)
to reduce such activity in rats given Cer+rolipram (1450±
30, 1600±50, 5500±250 and 4700±400 U/l, n=3, for rats
given saline+DMSO, saline+rolipram, Cer+DMSO and Cer+
rolipram, respectively, data not shown).ontrol or pancreatitic rats
9
P C P
0.2 4.4±1.2 3.1±2.8 4.0±3.0
1.0 7.1±0.4 2.7±2.6 3.0±1.9
0.06 0.6±0.2 0.7±0.9 1.5±1.1
1.3 87.9±0.6 93.5±5.6 91.5±5.4
s; S, soluble (cytosolic fraction). Rats: C, control (saline-injected); P, pancreatitic
nd methods, and are expressed as relative percentages considering the sum of the
ata are means±S.D. of 3 experiments with 4 rats in each.
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development of AP
Finally we analysed the subcellular distribution and dynamics
of both PTPs. As expected, both PTPs were completely (SHP-1,
data not shown) or mainly cytosolic (located in the S fraction,
Table 1). SHP-1 remained as a cytosolic enzyme along the
development of pancreatitis development and was never seen to
become associated with any subcellular membrane-fraction (data
not shown). By contrast, we observed that in the early phase of
AP (2 h), the increase in the expression of SHP-2 protein was
associated with significant increases in its location in the L+M
fraction, but mainly in the Mic subcellular fraction. This
redistribution was less marked at 4 h after the first injection of
Cer, and it disappeared at 9 h.
4. Discussion
AP involves a complex cascade of local and systemic events
that are initiated as a response to stress by the pancreatic acinar
cell, but the cellular and molecular mechanisms responsible of
the initiation of pancreatitis are not well understood. Acinar cell
responses in AP include not only rapid protein activation by
posttranslational modifications, but also alterations in gene and/
or protein expression that may convert the rapid activation of
signalling mechanisms in acinar cells into long-term responses
[1]. All these events, as a whole, will determine the ultimate
severity of AP.
It has been proposed that alterations in gene expression
within the initiation phase of AP play an important role in its
development [1]. Taking this into account, in this studywe report
an increase in SHP-1 and SHP-2 in the pancreas at the level
of both protein and mRNA as an early event during the
development of Cer-induced AP. Especially significant was the
increase in the expression of SHP-2 protein, because it was
observed commonly in all three different in vivo models of AP.
This highlights the general importance of the increase in the
expression of this PTP in AP. By contrast, the specificity of the
increase in SHP-1 protein in the Cer-induced AP model could
reflect a specific response to a specific insult.
It is known that both SHP-1 and SHP-2 are expressed in the
rat exocrine pancreas [12] and that both PTPs are scarcely
detectable in human neutrophils [31], which, together with the
data obtained here with vinblastine sulfate, indicates that the
increase in the expression of both PTPs most likely arises from
pancreatic acinar cells. Nevertheless, it is still possible that other
minor pancreatic cell types could account for some of the
observed changes. In this context, further studies are currently
being designed to fully determine the cellular origins of these
PTPs.
It has been reported that there is a common set of genes
expressed in at least Cer- and taurocholate-induced AP [1],
which suggests the possibility of a common set of upstream
signalling mechanisms. From previous studies, it is known that
the different AP models used here induce the activation of
stress kinases, including JNK [32]. Both JNK and ERK1/2
have been proposed to be important mediators during theearly phase (first 1–1.5 h) of AP [9,26,33]. Many of the
transcription factors (TFs) induced early on in the onset of AP
are known to be regulated by the activation of stress kinase
pathways [1]. Thus, the activation of stress kinases provides a
potential link between the earliest known signalling events in
AP and the long-term consequences that stem from changes
in gene expression. Furthermore, stress kinases also regulate
protein translation [34]. Since these enzymes have been re-
ported to promote gene and protein expression early on in
the development of Cer-induced AP [9,26], we decided to
analyse their potential influence in the observed increase of
both SHP-1 and SHP-2 proteins. We used SP600125, a new
MAPK inhibitor that, under the conditions used here, has been
described to almost totally inhibit Cer-induced pancreatic JNK
activation and partially inhibit ERK1/2 activation [9]. Our re-
sults demonstrated that SP600125 pre-treatment was able to
positively modulate both SHP-1 and SHP-2 protein expression
in the early phase of Cer-induced AP. Currently it is difficult
to envisage the mechanism by which the inhibition of MAPK
would afford further increases in both PTP proteins. It is pos-
sible that the observed effect could be mediated through an
effect on the half-life of early-activated TFs. It has been pro-
posed that the activation of TFs also facilitates their immediate
degradation, thus ensuring the end of translation activation [35].
It is possible that an inhibition of the MAPK pathway that
activates specific TFs might influence the concomitant degra-
dation rate of such TFs, thus modifying their half-life. Another
possibility would be an effect of JNK and/or ERK1/2 on the
half-life of both SHP-1 or SHP-2 proteins or messages. Further
specific research would be necessary to analyse this surprising
effect. Considering that MAPKs have also been shown to up-
regulate the expression of inflammatory cytokines, such as
TNF-α [9], which also primes cell infiltration in the pancreas,
and that SP600125 pre-treatment results in a blunted leukocyte
accumulation in the pancreases of Cer-induced AP rats [9], the
positive effects of SP600125 and the data on neutropenic rats
seem to be in good agreement. We believe that analyses of
infiltration as a regulator of at least SHP-2 protein expression
merit further investigation. The lack of a significant reduction
in amylase activity after SP600125 pre-treatment seems to be in
disagreement with previous results [9]. Nevertheless, it is im-
portant to recall that we were analysing the early phase of Cer-
induced AP and that those previous results [9] were found
in rats with fully developed AP. Therefore, the reduction in
amylase activity after JNK and ERK1/2 inhibition would occur
later on in the development of AP.
Excessive ATP catabolism has been reported to occur during
AP [20] and increases in cAMP levels in inflammatory cells by
rolipram have been reported to attenuate some inflammatory
diseases, including AP [27]. Rolipram is a specific and strong
inhibitor of type IV phosphodiesterase, a key enzyme in the
metabolism of intracellular cAMP that is abundantly expressed
in inflammatory cells such as neutrophils and that also exerts
anti-inflammatory effects by increasing the level of intracellular
cAMP by blocking its catalysis. Thus, rolipram has a similar
action to that of adenosine A2a receptors, a receptor type mainly
expressed in inflammatory cells [10]. Increases in intracellular
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kinase A and reduce the production of proinflammatory cyto-
kines such as TNF-α [36]. Importantly, acinar cells can behave
as true inflammatory cells, which also produce such proin-
flammatory cytokines [37]. Accordingly, although we are not
aware of any report describing the presence of type IV phos-
phodiesterase in acinar cells, rolipram could be a useful tool
for investigating the role of intracellular cAMP levels in cell
infiltration, and probably also in acinar cells, during the deve-
lopment of AP. Accordingly, analysis of the putative influence
of rolipram not only on infiltrating neutrophils but also on
acinar cells as a cause of the specific sensitivity of SHP-2
expression to rolipram deserves further investigation. Future
in vitro experiments with isolated acinar cells in the presence or
absence of neutrophils will be necessary to further increase our
understanding of the in vivo effect of rolipram on SHP-2 protein
expression in Cer-induced AP rats.
SHP-1 remained as a cytosolic enzyme during Cer-induced
AP development (this work), which is in agreement with pre-
vious results [12]. By contrast, the increase in SHP-2 in the early
phase of Cer-induced AP was associated with a redistribution
of its subcellular location. Preliminary data with three diffe-
rent lysosomal populations obtained by centrifugation of the
pancreatic L+M subcellular fraction in Percoll density gradients
revealed that SHP-2 significantly increases its location by
more than 100% (reaching up to 50% of total SHP-2 protein in
the L+M fraction) in the two densest populations (unpublished
results). Electron microscopic observations of these reveal that
they are composed of vesicles enclosing membrane fragments
and amorphous membrane-bound material of varying sizes and
shapes (unpublished results). Data on the intracellular proteo-
lytic systems used for PTP degradation are very scarce, although
it is generally accepted that most regulatory molecules involved
in highly regulated cellular processes such as signal transduc-
tion are substrates of the proteasome. Thus, the meaning of the
association of SHP-2 with lysosomes in AP is unknown. Despite
this, it should be noted that the lysosomal/vacuolar system is a
discontinuous and heterogeneous digestive system that also
includes structures that are devoid of hydrolases and that carry
out processes of heterophagy and autophagy [38], and that
autophagy has been reported to occur in AP [39]. It is possi-
ble that as a result of autophagy, membranous and/or non-
membranous material carrying SHP-2 protein could reach the
densest lysosomal populations. Moreover, SHP-2 protein was
also increased in the Mic subcellular fraction. At this point it is
not possible to know what this would be due to. One possibility
is the recruitment of SHP-2 to the plasma membrane by activa-
ted receptor protein tyrosine kinases or other phosphotyrosine-
containing ligands that occur early on in the development of AP
[40]. It should be noticed that most of the plasma membrane
would be present in theMic fraction in our fractionation method.
Finally, it is known that AP is associated with the disassembly of
the acinar cell cytoskeleton [41] and several lines of in vitro and
in vivo evidence suggest that SHP-2 might be involved in the
control of cytoskeletal architecture [40].
In sum, in this study we have detected an increase in SHP-1
and SHP-2 in the pancreas at the level of both protein andmARN as an early event during the development of Cer-
induced AP. The increase in SHP-2 protein (which was asso-
ciated with changes in its subcellular distribution) in two other
different in vivo pancreatitic models points towards the general
importance of this phosphatase in AP. The inhibition of JNK
and ERK1/2 further increased the expression of both SHP-1 and
SHP-2 proteins, while the inhibition of type IV phosphodies-
terase only suppressed the increase in SHP-2 protein expression
in the early phase of AP.
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